

Appl. No. 10/773,083  
Amdt. dated August 8, 2005

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-20 (cancelled)

Claim 21 (new)      A method of treating an IL-23 mediated disorder comprising administering an effective amount of an antagonist of IL-23, wherein the antagonist is an antigen binding fragment of an antibody or a soluble receptor derived from IL-23 receptor (IL-23R).

Claim 22 (new)-      The method of Claim 1 wherein the disorder is a gastrointestinal disorder.

Claim 23 (new)      The method of Claim 1, wherein the antibody is:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody;
- d) detectably labeled

Claim 24 (new)      The method of Claim 1, wherein the antigen binding fragment of the antibody is:

- a) humanized; or
- b) an Fab, Fv, or F(ab')<sub>2</sub> fragment.

Claim 25 (new)      The method of Claim 1, wherein the IL-23 mediated disorder is an inflammatory bowel disorder.

Appl. No. 10/773,083  
Amdt. dated August 8, 2005

**Claim 26 (new)**      The method of Claim 25, wherein the inflammatory bowel disorder is:

- a) Crohn's disease
- b) Ulcerative colitis
- c) Celiac disease

**Claim 27 (new)**      The method of Claim 25, wherein the inflammatory bowel disorder results in mucosal thickening, epithelial hyperplasia, inflammation of the submucosa or tunica muscularis, or infiltration by granulocytes or macrophages.

**Claim 28 (new)**      The method of Claim 1, wherein the antagonist of IL-23 inhibits:

- a) expression of IL-1 $\beta$  by a macrophage; or
- b) expression of TNF $\alpha$  by a macrophage.